The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $124.51

Today's change-2.71 -2.13%
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $124.51

Today's change-2.71 -2.13%
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc down (U.S.)$2.71

Alexion Pharmaceuticals Inc closed sharply lower Monday, dropping (U.S.)$2.71 or 2.13% to (U.S.)$124.51. Over the last five days, shares have lost 5.08% and are down 34.73% for the last year to date. This security has underperformed the S&P 500 by 27.70% during the last year.

Key company metrics

  • Open(U.S.) $127.22
  • Previous close(U.S.) $127.22
  • High(U.S.) $127.64
  • Low(U.S.) $124.21
  • Bid / Ask(U.S.) $124.50 / (U.S.) $142.49
  • YTD % change-34.73%
  • Volume1,484,700
  • Average volume (10-day)1,479,252
  • Average volume (1-month)1,281,552
  • Average volume (3-month)1,795,147
  • 52-week range(U.S.) $110.56 to (U.S.) $193.45
  • Beta1.33
  • Trailing P/E315.33×
  • P/E 1 year forward27.44×
  • Forward PEG1.50×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.39
Updated September 26 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue753701701667
Total other revenue--------
Total revenue753701701667
Gross profit692642643613
Total cost of revenue61595854
Total operating expense558535604512
Selling / general / administrative232233242213
Research & development179167191161
Depreciation / amortization80898041
Interest expense (income), net operating--------
Unusual expense (income)7-133343
Other operating expenses, total--------
Operating income19516697155
Interest income (expense), net non-operating---24-23--
Gain (loss) on sale of assets--------
Other--------
Income before tax17014475139
Income after tax1159267-184
Income tax, total55518323
Net income1159267-184
Total adjustments to net income--------
Net income before extra. items1159267-184
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1159267-184
Inc. avail. to common incl. extra. items1159267-184
Diluted net income1159267-184
Dilution adjustment--------
Diluted weighted average shares226227228226
Diluted EPS excluding extraordinary itemsvalue per share0.510.410.29-0.81
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share0.530.370.42-0.69